{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix E: ECOG/KPS Conversion Table', 'ECOG PERFORMANCE STATUS', 'KARNOFSKY PERFORMANCE STATUS', '100-Normal, no complaints; no evidence of', 'disease', '0-Fully active, able to carry on all pre-disease', 'performance without restriction', '90-Able to carry on normal activity; minor signs', 'or symptoms of disease', '80-Normal activity with effort, some signs or', 'symptoms of disease', '1-Restricted in physically strenuous activity but', 'ambulatory and able to carry out work of a light or', 'sedentary nature, e.g., light house work, office work', '70-Cares for self but unable to carry on normal', 'activity or to do active work', '60-Requires occasional assistance but is able', 'to care for most of personal needs', '2-Ambulatory and capable of all selfcare but unable to', 'carry out any work activities; up and about more than 50%', 'of waking hours', '50-Requires considerable assistance and', 'frequent medical care', '40-Disabled; requires special care and', 'assistance', '3-Capable of only limited selfcare; confined to bed or', 'chair more than 50% of waking hours', '30-Severely disabled; hospitalization is', 'indicated although death not imminent', '20-Very ill; hospitalization and active', 'supportive care necessary', '4-Completely disabled; cannot carry on any selfcare;', 'totally confined to bed or chair', '10-Moribund', '5-Dead', '0-Dead', '*Karnofsky D, Burchenal J, The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, ed.', 'Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:191-205.', '**Zubrod C, et al. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of', 'nitrogen mustard and thiophosphoramide. Journal of Chronic Diseases; 1960:11:7-33.', 'Page 48 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix F: Overall Treatment Utility Form', 'Patient Name:', 'Patient ID:', 'Date:', 'Overall Treatment Utility (OTU)', 'OTU is a novel clinical outcome measure incorporating objective and subjective measures of anticancer', 'efficacy, tolerability and acceptability, assessed 12 weeks after starting treatment and condensed into a', 'simple 3-point score.', 'OTU may be regarded as asking the clinician: \"With the benefit of hindsight, are you glad you gave this', 'treatment?\" and asking the patient: \"With the benefit of hindsight, are you glad you received it?\": OTU', 'is scored as good, intermediate or poor, corresponding to \"yes\", \"uncertain\" or \"no\" replies to these', 'questions.', 'To score OTU, the patient is assessed 12 weeks after randomisation (acceptable window 10-14 weeks),', 'using the following criteria:', '1. Clinical benefit? Categorised as:', 'a. Both radiologically progression-free (RECIST response or stable disease)', 'and no clinical deterioration\u00b2, as assessed by treating consultant', 'b. Either radiological progression (RECIST progressive disease)', 'or clinical deterioration, as assessed by treating consultant', '2. Tolerable and acceptable? Categorised as:', 'a. All of the following:', 'no SAE or SUSAR attributed to treatment', 'no episodes of grade >3 non-haematological toxicity', '2', 'patient response to LHA Q37 (\"How much has your treatment interfered with your', 'normal daily activities?\") is not \"Very much\"', 'patient response to LHA\u00b2 Q38 (\"How worthwhile do you think your treatment has', 'been?\") is not \"Not at all\"', 'b. Any of the following:', 'an SAE or SUSAR attributed to treatment', 'an episode of grade >3 non-haematological toxicity', 'patient response to LHA\u00b2 Q37 (\"How much has your treatment interfered with your', 'normal daily activities?\") is \"Very much\"', 'patient response to LHA\u00b2 Q38 (\"How worthwhile do you think your treatment has', 'been?\") is \"Not at all\"', 'Scoring:', 'Good OTU:', 'Patient is alive and scores 1a/2a', 'Intermediate OTU:', 'Patient is alive and scores 1a/2b or 1b/2a', 'Poor OTU:', 'Patient is alive and scores 1b/2b, or patient is dead', '1 Clinical deterioration = clear clinical evidence of cancer progression which has not been confirmed radiologically.', '2 LHA = Limited Heath Assessment Please see webappendix pages 9-13 for full details of the LHA.', 'Investigator Signature', 'Date', 'Page 49 of 52']\n\n###\n\n", "completion": "END"}